Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research note published on Monday. The brokerage issued a hold rating on the stock.

A number of other equities research analysts have also weighed in on EKSO. HC Wainwright reiterated a buy rating and set a $10.00 price objective on shares of Ekso Bionics in a report on Tuesday, July 30th. Lake Street Capital started coverage on shares of Ekso Bionics in a research note on Monday, June 24th. They set a buy rating and a $2.50 price target for the company.

Ekso Bionics Trading Down 1.6 %

EKSO opened at $1.20 on Monday. Ekso Bionics has a one year low of $0.62 and a one year high of $3.13. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. The stock has a market cap of $21.81 million, a price-to-earnings ratio of -1.24 and a beta of 1.45. The stock’s 50 day moving average price is $1.13 and its 200-day moving average price is $1.22.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same quarter in the previous year, the business earned ($0.31) EPS. On average, equities analysts forecast that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC raised its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.